Hansa Biopharma trial results to be presented at transplant congress
Tweet Send to a Friend
Hansa Biopharma AB (NASDAQ Stockholm: HNSA) announced that results from its Phase 3 ConfIdeS trial in kidney transplantation have been ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
